SpaceX’s Starfall Test Flight: A New Frontier in Cargo Delivery
On Tuesday, June 23, a SpaceX Falcon 9 lifted off from Cape Canaveral carrying a vehicle most people had never heard of. The payload was called Starfall — a disc-shaped reentry pod, 10.2 feet wide and 2.5 feet tall, designed to carry up to 1 metric ton of cargo from low-Earth orbit back to Earth’s surface.
Space Exploration Technologies (SPCX) described it publicly as a “microgravity lab” for scientific research and in-space manufacturing. What the Federal Aviation Administration’s environmental assessment called it was more specific: a vehicle to “enable point-to-point delivery of critical cargo through space on rapid timelines.”
Two Markets to Pay Attention to
Two markets emerge immediately from that design profile. The first is military logistics. The Pentagon has been working toward a space-based point-to-point cargo delivery capability for years. In 2022, the Air Force Research Laboratory awarded SpaceX a $102 million contract to demonstrate the concept using Starship — the ability to deliver roughly a C-17 Globemaster’s worth of supplies anywhere on the planet in under 90 minutes.
Starfall, smaller and deployable on the existing Falcon 9, is a complementary tool for lighter, more targeted deliveries that don’t require Starship’s enormous footprint or a prepared landing site. The Pentagon has signed similar early-stage agreements with Rocket Lab (RKLB), Blue Origin, and Anduril for reentry vehicle development. SpaceX is the only company flying a working vehicle today.
For more information on SpaceX Starship, please visit our website.
Commercial In-Space Manufacturing
The second market is commercial in-space manufacturing, and it’s further along than most people realize. Varda Space Industries signed a partnership with United Therapeutics in May 2026 to manufacture drugs in microgravity — specifically targeting small-molecule crystallization processes that Earth’s gravity renders structurally imperfect.
Varda CEO Will Bruey put the economics plainly at the 2026 Upfront Summit: A launch capable of processing space-manufactured drugs and returning them to Earth now costs roughly $2.2 million — a number that makes pharmaceutical microgravity viable at commercial scale for the first time. Starfall, with its 1-metric-ton payload capacity and reusable design, is positioned as the return infrastructure that makes that supply chain possible at volume.
For more information on In Space Manufacturing, please visit our website.
What This Means for SPCX Shareholders
Starfall’s commercial potential is real, but the timelines are long, and the revenue is not yet material on SpaceX’s financials. The company’s near-term revenue story is Starlink, which generated $4.42 billion in operating income in 2025 and remains the only profitable segment.
Even in an optimistic scenario where it wins military contracts and becomes the backbone of orbital pharmaceutical manufacturing, Starfall adds revenue on a multiyear timeline. For investors looking at SpaceX in a week when the stock has already fallen nearly 30% from its peak due to valuation and float concerns, Starfall is the kind of development that validates the long-term thesis without changing the short-term math.
For more information on SpaceX Stock Price, please visit our website.
Conclusion
The question that was true before Tuesday and remains true after it is whether the current price — which sits 53% above Morningstar’s base-case intrinsic value — gives investors enough room for execution risk on programs that haven’t yet generated meaningful revenue.
The technology is not what’s in question. The valuation still is. As Indian investors, it’s essential to stay informed about the latest developments in the stock market and make informed decisions based on your investment goals and risk tolerance.
For more information on Indian Stock Market, please visit our website.